What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to provide updated financial guidance for Eli Lilly & Co., confirming their 2011 outlook and releasing their financial expectations for 2012. It also details the non-GAAP financial measures the company uses.

What specific items are excluded when Eli Lilly presents its non-GAAP earnings?

When presenting non-GAAP earnings, Eli Lilly excludes restructuring charges (severance costs), in-process research and development charges (from the Boehringer Ingelheim diabetes collaboration), and estimated asset impairment charges (related to the Xigris withdrawal).

Why does Eli Lilly use non-GAAP financial measures?

Eli Lilly uses non-GAAP measures to provide investors with a clearer view of the company's ongoing operational performance. They believe these measures help in making more meaningful period-over-period comparisons and in identifying operating trends that might otherwise be obscured by volatile or significant one-time items.

Are investors advised to rely solely on the non-GAAP figures?

No, investors are advised to consider the non-GAAP measures in addition to, and not as a substitute for or superior to, financial performance measures prepared in accordance with GAAP. The company emphasizes that GAAP measures provide the foundational financial reporting.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) filed an 8-K on January 5, 2012, to provide updates on their financial guidance for both 2011 and 2012. The company confirmed its previously issued guidance for the full year 2011 and also released its financial expectations for 2012. A key aspect of this filing is the company's use of non-GAAP financial measures to present earnings per share, which exclude certain significant items. These excluded items are primarily restructuring charges related to workforce reductions, in-process research and development costs associated with a diabetes collaboration, and an estimated asset impairment charge due to the withdrawal of Xigris. Lilly states that these non-GAAP measures are intended to provide investors with a clearer view of ongoing operational performance and to facilitate meaningful comparisons over time. Investors are advised to consider these non-GAAP figures in conjunction with, rather than as a replacement for, GAAP measures.

Key Highlights

1Confirmation of 2011 financial guidance.
2Announcement of 2012 financial guidance, presented on both GAAP and non-GAAP bases.
3Detailed explanation of non-GAAP financial measures used by the company.
4Exclusion of restructuring charges related to strategic cost-reduction initiatives from non-GAAP earnings.
5Exclusion of in-process R&D charges from a diabetes collaboration with Boehringer Ingelheim from non-GAAP earnings.
6Exclusion of an estimated asset impairment charge for Xigris withdrawal from non-GAAP earnings.
7Emphasis that non-GAAP measures are intended to enhance understanding of ongoing operations and trend analysis.

ELI LILLY & Co 8-K Report, Financial Results (Jan 5, 2012)

Summary

Key Highlights

Frequently Asked Questions